Stock · GILD · Healthcare
United States · Large Cap · listed since 1992 · Revenue 12 mo. $30.5B
Price as of 11/06/2026
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
Original text from the data provider
Summary
61.1 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €8.5B (2025), it supports €94.3B. The remaining €91.9B of the market value assume it grows 9.5% a year for 10 years and not at all afterwards.
Required FCF growth per year
9.5%
no growth afterwards
Price to operating cash flow 15.3×, above its usual range.
Middle half of 20 quarters: 9.8× to 12.9×, median 11.4×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
3 more unchanged: Revenue, 12 mo., Gross margin, Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 37.49% | 11.52% | Rank 90 |
| Return on capital (Greenblatt) | 96.42% | 32.55% | Rank 91 |
| EBIT margin | 39.74% | 18.31% | Rank 95 |
| FCF margin | 32.12% | 14.12% | Rank 94 |
| Gross margin | 78.83% | 60.99% | Rank 83 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 2.39% | 8.04% | Rank 21 |
| Earnings growth, 3 years per year | 23.06% | 5.44% | Rank 78 |
| Earnings growth, 5 years per year | 133.65% | 7.00% | Rank 100 |
| Sustainable growth (ROE × retained earnings) | 1.91% | 3.66% | Rank 22 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 4.06% | 2.90% | Rank 70 |
| FCF yield | 4.56% | 3.63% | Rank 64 |
| EV/saleslower is better | 7.57 | 4.03 | Rank 25 |
| EV/EBITlower is better | 19.04 | 21.73 | Rank 58 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 25.64% | 8.66% | Rank 75 |
| Share price, 6 months | 27.56% | 24.27% | Rank 59 |
| Share price, 3 months | 30.41% | 15.42% | Rank 90 |
| Distance from 52-week high | −4.35% | −7.35% | Rank 64 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 5.57% | 0.30% | Rank 16 |
| Change in share countlower is better | 0.00% | 0.00% | Rank 45 |
| Dividend streak in years | 10 | 10 | Rank 61 |
| Price reaction to results, market-adjusted | 4.66% | 0.05% | Rank 84 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 38.46% | 48.40% | Rank 29 |
| Net debt/EBITDAlower is better | 1.13 | 1.11 | Rank 49 |
| Debt to equitylower is better | 1.10 | 0.48 | Rank 17 |
| Volatility, 1 yearlower is better | 27.16% | 31.42% | Rank 78 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 30.4 | 58.0% | 16.3 | 1.36B | 18.1 |
| 2017 | 26.1 | 54.1% | 11.3 | 1.32B | 26.0 |
| 2018 | 22.1 | 37.1% | 7.5 | 1.31B | 9.4 |
| 2019 | 22.4 | 19.1% | 8.3 | 1.28B | 13.0 |
| 2020 | 24.7 | 16.5% | 7.5 | 1.26B | 25.4 |
| 2021 | 27.3 | 36.3% | 10.8 | 1.26B | 21.4 |
| 2022 | 27.3 | 26.9% | 8.3 | 1.26B | 19.8 |
| 2023 | 27.1 | 28.1% | 7.4 | 1.26B | 18.9 |
| 2024 | 28.8 | 5.8% | 10.3 | 1.26B | 16.7 |
| 2025 | 29.4 | 39.7% | 9.5 | 1.26B | 17.4 |
6 of 7 StockScorer Score rules met · How the score is built
Gilead Sciences Inc mainly meets criteria in the Profitability category. Result from 18 strategies checked.
Gilead Sciences Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
6 of 7 rules met
9 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Gilead Sciences Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 24.6 | 30.0 |
| P/B ratio | 9.2 | 4.8 |
| Return on equity (ROE) | 37.5% | 11.5% |
| Equity ratio | 38.5% | 48.4% |
| Debt-to-equity (D/E) | 1.10 | 0.48 |
| Dividend yield | 1.9% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| GILD | Gilead Sciences Incthis page | |
| PFE | Pfizer Inc | Medium5.5 |
| AMGN | Amgen Inc | Medium5.5 |
| BMY | Bristol-Myers Squibb Company | High7.3 |
| MRK | Merck & Company Inc | locked |
| ABBV | AbbVie Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.